APP Pulse Episode 2: Hitting the Target: ADCs Explained

ADC use is expanding, and APPs play a central role in counseling patients and in identifying and managing toxicities. This episode explores the evolving role of antibody-drug conjugates in gynecologic cancer treatment and highlights current evidence, clinical application and future directions for improving patient outcomes. It provides expert insights into how these target therapies are shaping the landscape of ovarian, endometrial and cervical cancer care. This episode will give APPs plain language they can use with patients, a framework for predicting and managing side effects, and insights on how dose reduction can preserve quality of life while maintaining response.Hosts: Nicole Dreibelbis, CRNP, WHNP-BC, Sarah Irish, DNP, APRN, FNP-BCGuest: Jennifer MacDonald, PharmD, BCOPSuggested Resource: https://www.sciencedirect.com/science/article/pii/S2352578923000103